Similar articles

• Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.

  Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, Hulse G, O'Neil G. Jeffrey GP, et al. Hepatology. 2007 Jan;45(1):111-7. doi: 10.1002/hep.21470. Hepatology. 2007. PMID: 17187435 Clinical Trial.
• Hepatitis C treatment for injection drug users: a review of the available evidence.

  Hellard M, Sacks-Davis R, Gold J. Hellard M, et al. Clin Infect Dis. 2009 Aug 15;49(4):561-73. doi: 10.1086/600304. Clin Infect Dis. 2009. PMID: 19589081 Review.
• Management of hepatitis C in Rhode Island: opportunities for improvement within and beyond the department of corrections.

  Berzin T, Allen S, Taylor L, Rich J, Feller E. Berzin T, et al. Med Health R I. 2002 Nov;85(11):341-4. Med Health R I. 2002. PMID: 12462866 No abstract available.
• [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].

  Lucidarme D. Lucidarme D. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B112-20. Gastroenterol Clin Biol. 2002. PMID: 12180278 Review. French. No abstract available.
• [Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection].

  Lozano Polo JL, Gutiérrez Mora E, Martínez Pérez V, Santamaría Gutiérrez J, Vada Sánchez J, Vallejo Correas JA. Lozano Polo JL, et al. Rev Clin Esp. 1997 Jul;197(7):479-83. Rev Clin Esp. 1997. PMID: 9411543 Clinical Trial. Spanish.